Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNa Homolce Hospital

About this trial

The optimal timing of surgical intervention in asymptomatic patients with severe aortic regurgitation remains controversial. As per cardiac magnetic resonance assessment, early surgical treatment will be compared with conventional guideline-based strategy in asymptomatic patients with severe aortic regurgitation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Chronic asymptomatic aortic regurgitation grade 3 (moderate to severe) and grade 4 (severe)

No indication for the surgical treatment at the time of enrolment

LV ejection fraction >50%

Absence of more than mild-to-moderate concomitant valve disease or complex congenital heart disease

Disqualifiers

Age <18 years

Clearance Creatinine <30 mL/min

Contraindication for magnetic resonance (implanted active device, ferromagnetic implant incompatible with magnetic resonance scanner, cerebral aneurysm clip, metallic fragment in the eye or near sensitive tissue)

Pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • State of art aortic valve surgery

    Procedure/Surgery

    Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).

Treatment groups

217 Participants
are divided into 2 treatment groups
Group A: Early surgeryExperimental treatment 1 intervention
Group B: Watchful waitingNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Composite safety and efficacy endpoint at 12 months post-randomization (all 3 criteria must be fulfilled):

1. Reverse LV remodelling (CMR-derived EDVI decrease \>15% compared to baseline) 2. LV ejection fraction \>50% 3. Absence of MACE (cardiovascular mortality, stroke, myocardial infarction, heart failure, infective endocarditis)

Time frame
12 months

Secondary outcomes

1

Change in comparison to baseline:

1\) Quality of life questionnaire \>10%

Time frame
12 months
2

Change in comparison to baseline:

2\) Spiroergometry - maximal oxygen consumption (VO2 max) \>10% and/or \>3 ml/kg/min

Time frame
12 months
3

Normalization of N-terminal pro B-natriuretic peptide serum level

NT-proBNP \<112 ng/L

Time frame
12 months
4

In hospital and 30 days mortality

Perioperative and/or early postoperative mortality

Time frame
30 day postoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Na Homolce Hospital

Lead sponsor

University Hospital Hradec Kralove

Collaborator

Centre of Cardiovascular and Transplantation Surgery, Czech Republic

Collaborator

St. Anne's University Hospital Brno, Czech Republic

Collaborator

VZW Cardiovascular Research Center Aalst

Collaborator

General University Hospital, Prague

Collaborator

University Clinical Centre of Republic of Srpska

Collaborator

AGEL Třinec-Podlesí Hospital

Collaborator